Cargando…
SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1(+) myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 8...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119413/ https://www.ncbi.nlm.nih.gov/pubmed/33986412 http://dx.doi.org/10.1038/s41598-021-89786-0 |
_version_ | 1783691849640181760 |
---|---|
author | Ostendorf, Lennard Dittert, Philipp Biesen, Robert Duchow, Ankelien Stiglbauer, Victoria Ruprecht, Klemens Bellmann-Strobl, Judith Seelow, Dominik Stenzel, Werner Niesner, Raluca A. Hauser, Anja E. Paul, Friedemann Radbruch, Helena |
author_facet | Ostendorf, Lennard Dittert, Philipp Biesen, Robert Duchow, Ankelien Stiglbauer, Victoria Ruprecht, Klemens Bellmann-Strobl, Judith Seelow, Dominik Stenzel, Werner Niesner, Raluca A. Hauser, Anja E. Paul, Friedemann Radbruch, Helena |
author_sort | Ostendorf, Lennard |
collection | PubMed |
description | We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1(+) myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 86 MS patients, 41 NMOSD patients and 31 healthy controls. Additionally, we histologically evaluated the presence of SIGLEC1(+) myeloid cells in acute and chronic MS brain lesions as well as other neurological diseases. We found elevated SIGLEC1 expression in 16/86 (18.6%) MS patients and 4/41 (9.8%) NMOSD patients. Almost all MS patients with high SIGLEC1 levels received exogenous interferon beta as an immunomodulatory treatment and only a small fraction of MS patients without interferon treatment had increased SIGLEC1 expression. In our cohort, SIGLEC1 expression on monocytes was—apart from those patients receiving interferon treatment—not significantly increased in patients with MS and NMOSD, nor were levels associated with more severe disease. SIGLEC1(+) myeloid cells were abundantly present in active MS lesions as well as in a range of acute infectious and malignant diseases of the central nervous system, but not chronic MS lesions. The presence of SIGLEC1(+) myeloid cells in brain lesions could be used to investigate the activity in an inflammatory CNS lesion. |
format | Online Article Text |
id | pubmed-8119413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81194132021-05-14 SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients Ostendorf, Lennard Dittert, Philipp Biesen, Robert Duchow, Ankelien Stiglbauer, Victoria Ruprecht, Klemens Bellmann-Strobl, Judith Seelow, Dominik Stenzel, Werner Niesner, Raluca A. Hauser, Anja E. Paul, Friedemann Radbruch, Helena Sci Rep Article We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1(+) myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 86 MS patients, 41 NMOSD patients and 31 healthy controls. Additionally, we histologically evaluated the presence of SIGLEC1(+) myeloid cells in acute and chronic MS brain lesions as well as other neurological diseases. We found elevated SIGLEC1 expression in 16/86 (18.6%) MS patients and 4/41 (9.8%) NMOSD patients. Almost all MS patients with high SIGLEC1 levels received exogenous interferon beta as an immunomodulatory treatment and only a small fraction of MS patients without interferon treatment had increased SIGLEC1 expression. In our cohort, SIGLEC1 expression on monocytes was—apart from those patients receiving interferon treatment—not significantly increased in patients with MS and NMOSD, nor were levels associated with more severe disease. SIGLEC1(+) myeloid cells were abundantly present in active MS lesions as well as in a range of acute infectious and malignant diseases of the central nervous system, but not chronic MS lesions. The presence of SIGLEC1(+) myeloid cells in brain lesions could be used to investigate the activity in an inflammatory CNS lesion. Nature Publishing Group UK 2021-05-13 /pmc/articles/PMC8119413/ /pubmed/33986412 http://dx.doi.org/10.1038/s41598-021-89786-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Ostendorf, Lennard Dittert, Philipp Biesen, Robert Duchow, Ankelien Stiglbauer, Victoria Ruprecht, Klemens Bellmann-Strobl, Judith Seelow, Dominik Stenzel, Werner Niesner, Raluca A. Hauser, Anja E. Paul, Friedemann Radbruch, Helena SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients |
title | SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients |
title_full | SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients |
title_fullStr | SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients |
title_full_unstemmed | SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients |
title_short | SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients |
title_sort | siglec1 (cd169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119413/ https://www.ncbi.nlm.nih.gov/pubmed/33986412 http://dx.doi.org/10.1038/s41598-021-89786-0 |
work_keys_str_mv | AT ostendorflennard siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT dittertphilipp siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT biesenrobert siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT duchowankelien siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT stiglbauervictoria siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT ruprechtklemens siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT bellmannstrobljudith siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT seelowdominik siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT stenzelwerner siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT niesnerralucaa siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT hauseranjae siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT paulfriedemann siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT radbruchhelena siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients |